Abstracts tagged "Disease Activity"

Abstract Number: 1666 • ACR Convergence 2021
Association of Objectively Measured Sleep Characteristics with Rheumatoid Arthritis Disease Activity
Patricia Katz¹, Sarah Patterson², Mary Nakamura³, Aric Prather¹, Laura Trupin⁴, Stephanie Rush¹ and Katie Stone¹, ¹University of California San Francisco, San Francisco, CA, ²University of California San Francisco, Pacifica, CA, ³UCSF/SFVAHCS, San Francisco, CA, ⁴UC San Francisco, San Francisco, CA
Background/Purpose: A large proportion of individuals with rheumatoid arthritis (RA), between 45%-70%, report sleep problems. Despite frequent reports of sleep problems, however, studies using objective…
Abstract Number: 1887 • ACR Convergence 2021
Evidence-Based Behçet’s Disease Activity Scale (EBDA) – A New Instrument with Improved Acuity for Major Organ Disease Activity and Remission Depth Assessment
Maria Caterina Lagdameo¹, Hyungrok Do² and Johannes Nowatzky¹, ¹Division of Rheumatology, New York University School of Medicine, New York, NY, ²Department of Population Health, NYU School of Medicine, New York
Background/Purpose: Most current Behçet’s disease (BD) activity assessment tools are strongly based on patient-reported symptoms and findings allowing a wide range of observer-dependent interpretations and…
Abstract Number: 0247 • ACR Convergence 2020
Lupus Low Disease Activity State Achievement Is Important for Reducing Adverse Outcomes in Pregnant Patients with Systemic Lupus Erythematosus
Ji-Won Kim¹, Ju-Yang Jung¹, Hyoun-Ah Kim¹ and Chang-Hee Suh¹, ¹Ajou university school of medicine, Suwon, Republic of Korea
Background/Purpose: This study aimed to examine the frequency and risk factors of complications during pregnancy in women with systemic lupus erythematosus (SLE).Methods: The medical records…
Abstract Number: 0360 • ACR Convergence 2020
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from German Observational Study
Elke Riechers¹, Uta Kiltz², Jan Brandt-Jürgens³, Peter Kästner⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ⁴Ambulantes Rheumazentrum, Erfurt, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Several studies have shown an negative association between smoking status and psoriatic arthritis (PsA) clinical outcomes1,2. The German non-interventional study AQUILA provides real-world data…
Abstract Number: 0746 • ACR Convergence 2020
HDL-bound yRNA-derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis
Qiong Wu¹, Quanhu Sheng¹, Joseph Solus¹, Danielle Michell¹, Kasey Vickers¹, Ryan Allen¹, C. Michael Stein¹ and Michelle Ormseth¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Small RNAs (sRNAs), including microRNAs (miRNAs) and yRNA-derived sRNAs (yDRs), are important gene regulators and markers of disease. HDL, while known for its anti-atherogenic…
Abstract Number: 0871 • ACR Convergence 2020
Hydroxychloroquine Dose Reduction and SLE Flares
April Jorge¹, Gary Ho², Michael Wu², Karen Costenbader³ and Hyon Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: 2016 ophthalmology guidelines recommend using hydroxychloroquine (HCQ) dosages < 5mg/kg/day, which is lower than the traditional 400mg/day for the majority of SLE patients. However,…
Abstract Number: 1141 • ACR Convergence 2020
Reversing Seasonal Decline of T2T Outcome in RA Patients Under Double Hits by Chinese New Year and COVID-19 Epidemic via Online Interaction with SSDM
Rong Mu¹, Hongbin Li², Zhanyun Da³, Anbin Huang⁴, Hongzhi Wang⁵, Jing Lu⁶, Jianhong Wu⁷, Shengtao Zhang⁸, Yikai Yu⁹, Chun Li¹⁰, Shouxin Li⁹, Peng Ji¹¹, Hua Wei¹², Bin Wu¹³, Zhenbin Li¹⁴, Lingxun Shen¹⁵, Yanping Zhao¹⁶, Yi Zhao¹⁷, Xiaoqiang Hou¹⁸, Hui Xiao¹⁹, Yuhua Jia²⁰, Bing Wu²⁰, Yonggang Zhao²⁰, Xin Chen¹⁹, Miaomiao Song²⁰, Fei Xiao²⁰ and Zhanguo Li²¹, ¹People's Hospital, Beijing University Medical School, Beijing, Beijing, China (People's Republic), ²The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ³The affiliated Hospital of Nantong University, Nantong, Jiangsu, China (People's Republic), ⁴Union Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, WuHan, China (People's Republic), ⁵The First Hospital of Jiaxing, Jiaxing, China (People's Republic), ⁶First Affiliated Hospital of China Medical University, Shenyang, China (People's Republic), ⁷Department of Rheumatology, Dazhou Central Hospital, Dazhou, China (People's Republic), ⁸Tongji Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China (People's Republic), ⁹Tongji Hospital Affiliated to Tongji Medical College of HUST, Wuhan, Hubei, China (People's Republic), ¹⁰People's Hospital, Beijing University Medical School, beijing, China (People's Republic), ¹¹The first affiliated hospital of xinjiang medical university, Urumqi, Xinjiang, China (People's Republic), ¹²Northern Jiangsu People's Hospital, Yangzhou, China (People's Republic), ¹³Chongqing Hospital of Traditional Chinese Medicine, chongqing, China (People's Republic), ¹⁴Chinese people ’s liberation army joint service support force 980 hospital, shijiazhuang, Jiangxi, China (People's Republic), ¹⁵Union Hospital Affiliated Tongji Medical College of HUST, Wuhan, Hubei, China (People's Republic), ¹⁶First Affiliated Hospital of Harbin Medical University, Harbin, China (People's Republic), ¹⁷Xuanwu Hospital, Capital Medical University, Beijing, China, Beijing, China (People's Republic), ¹⁸Yichang Central People's Hospital, Beijing, China (People's Republic), ¹⁹Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ²⁰Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ²¹Peking University People’s Hospital, Xicheng, Beijing, China (People's Republic)
Background/Purpose: Treat-to-target (T2T), achieving a DAS28 below 3.2 is the main management strategy for RA. The Chinese New Year is a long holiday started in…
Abstract Number: 1286 • ACR Convergence 2020
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus by Physician Global Assessment of Disease Activity
May Choi¹, Emma Stevens², Hongshu Guan², Daniel Li³, Jack Ellrodt⁴, Benjamin Kargere⁴, Tianrun Cai², Kazuki Yoshida⁵, Brendan Everett² and Karen Costenbader⁶, ¹Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital, Boston, MA, ³Harvard, Columbus, OH, ⁴Williams College, Williamstown, ⁵Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The risk of cardiovascular disease (CVD), including myocardial infarction and stroke, is higher in SLE than in the general population. The excess risk of…
Abstract Number: 1548 • ACR Convergence 2020
Blood Pressure, BMI and Sex Affect Optical Spectral Transmission Imaging Measurements of the Hands
Annelies Blanken¹, Conny van der Laken² and Mike Nurmohamed³, ¹Amsterdam Rheumatology and immunology Center location Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, location Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands
Background/Purpose: Optical spectral transmission imaging (OST) is a new imaging method designed to measure inflammation in the hands of rheumatoid arthritis (RA) patients. The device…
Abstract Number: 1732 • ACR Convergence 2020
Machine Learning Coupled with Patient Reported Outcome Data to Classify & Predict RA Disease Activity
Jeffrey R Curtis¹, Fenglong Xie², Shelly Kafka³ and Shawn Black³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Patient reported outcome (PRO) data have assumed increasing importance in the care of rheumatoid arthritis (RA) patients. However, physician-derived disease activity measures such as…
Abstract Number: 1851 • ACR Convergence 2020
Different Disease Activity Trajectories in Early Axial Spondyloarthritis Lead to Significantly Different Long-term Outcomes : A Cluster-based Analysis of the DESIR Cohort
Benattar Leslie¹, Anna Molto², Laure Gossec³ and Resche Rigon Matthieu⁴, ¹Cochin Hospital, Paris, Paris, Ile-de-France, France, ²Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, ³Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ⁴INSERM (UFR 1153), Saint Louis Hospital, Paris, Paris, France
Background/Purpose: AxSpA is a heterogeneous disease, leading to different treatment and follow-up modalities depending on the presentation, along with other elements (socio-economic, gender, etc..). In a…
Abstract Number: 0003 • ACR Convergence 2020
Assessing Cytokine Profiles and COVID Serology in Patients on Immunosuppression to Guide Care Recommendations
Quinn Pritchett¹, Rebecca Overbury¹, Dorota Lebiedz-Odrobina¹, Julie Thomas¹, Tawnie Braaten², Stacey Clardy¹, Marc Elgort³, Emily Spivak¹, Patricia Slev³, Lisa Peterson³ and Tracy Frech⁴, ¹University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City, ³ARUP, Salt Lake City, UT, ⁴University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: The COVID-19 pandemic is especially terrifying for patients on immunosuppression for autoimmune disease. With the exception of social isolation, experts do not have clear…
Abstract Number: 0249 • ACR Convergence 2020
Validation of the SIMPLE Index for Disease Activity of Systemic Lupus Erythematosus in Chinese Patients
Chi Chiu Mok¹, Ling Yin Ho¹, Kar Li Chan² and Meenakshi Jolly³, ¹Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Rush University, Chicago, IL
Background/Purpose: The SIMPLE (SIMple Disease Assessment for People with Lupus Erythematosus) index is a composite numeric tool that captures disease activity from patients’ self-assessment with…
Abstract Number: 0361 • ACR Convergence 2020
Response to Treatment with Ixekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis Based on HLA-B27 Status and Disease Duration
Victoria Navarro-Compán¹, Jose Maldonado-Cocco², Proton Rahman³, Andris Kronbergs⁴, David Sandoval⁴, So Young Park⁴, Theresa Hunter⁴ and Marina Magrey⁵, ¹Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ²University of Buenos Aires School of Medicine, Buenos Aires, Argentina, ³Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁴Eli Lilly and Company, Indianapolis, ⁵Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: In this analysis, we evaluate the efficacy of ixekizumab at week 16 in patients with non-radiographic axial spondyloarthritis (nr-axSpA) with or without baseline HLA-B27…
Abstract Number: 0751 • ACR Convergence 2020
Serum Interferon-Alpha Levels Could Help Identify a Subgroup of Rheumatoid Arthritis with Poorer Physical Function and Higher Physician Global Assessment
Yong Gil Hwang¹, Lei Zhu², Dongwen Wu² and Larry Moreland³, ¹University of Pittsburgh Physicians, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Colorado, Colorado
Background/Purpose: Our objective was to identify the clinical significance of serum interferon-alpha levels in patients with established rheumatoid arthritis (RA).Methods: Serum samples and clinical data…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].